Cancer
Conditions
Interventions
Participants will be randomised into two groups in the study:
Group 1 Cessation of medical therapy
Group 2 Continuation of medical therapy
Randomisation will be in random permuted blockers to either g
Sponsors
Miyazaki Sakiko
Sydney University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria Previously diagnosed asymptomatic chemotherapy related cardiac dysfunction (CTRCD) LVEF of >50%. NYHA Class I Current CTRCD therapy Angiotensin Converting Enzyme inhibitor (ACEi) plusminus Beta Blocker (BB) Completed anthracycline AND HER2 receptor therapy
Exclusion criteria
Exclusion criteria: Exclusion criteria: History of ischaemic heart disease Hypertension requiring medical therapy Moderate or greater severity valvular disease Chronic kidney disease Atrial, supraventricular, or ventricular arrhythmia requiring BB therapy Pregnancy under 16 years old Contraindication to cardiac magnetic resonance imaging
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in Left Ventricular Ejection Fraction (LVEF) by cardiac magnetic resonance imaging at six months of enrolment | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) score Change in EQ-5D questionnaire score Heart failure requiring hospital admission Worsening heart failure requiring medical treatment as adjudicated by the independent cardiologist. Changes in cardiac volumes and functions including global longitudinal strain (GLS) by echocardiographyChanges in cardiac volumes assessed with cardiac MRI Change in blood test values of the following Hs-troponin , NT-proBNP | — |
Countries
Austraria, Japan, Syngapore
Contacts
Public ContactSakiko Miyazaki
Juntendo University, School of Medicine
Outcome results
None listed